How imiquimod licenses plasmacytoid dendritic cells to kill tumors

We have provided evidence for a multifaceted antitumor-function of the Toll-like receptor 7 (TLR7) agonist imiquimod, which rapidly recruits plasmacytoid dendritic cells and possibly other immune cells into tumors by inducing the secretion of CCL2 by dermal cells. Imiquimod induces pDC maturation an...

Descripción completa

Detalles Bibliográficos
Autores principales: Holcmann, Martin, Drobits, Barbara, Sibilia, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525638/
https://www.ncbi.nlm.nih.gov/pubmed/23264929
http://dx.doi.org/10.4161/onci.22033
_version_ 1782253453476626432
author Holcmann, Martin
Drobits, Barbara
Sibilia, Maria
author_facet Holcmann, Martin
Drobits, Barbara
Sibilia, Maria
author_sort Holcmann, Martin
collection PubMed
description We have provided evidence for a multifaceted antitumor-function of the Toll-like receptor 7 (TLR7) agonist imiquimod, which rapidly recruits plasmacytoid dendritic cells and possibly other immune cells into tumors by inducing the secretion of CCL2 by dermal cells. Imiquimod induces pDC maturation and their conversion into cytolytic killer cells, which are capable of eliminating tumors independently from the adaptive immune system.
format Online
Article
Text
id pubmed-3525638
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35256382012-12-21 How imiquimod licenses plasmacytoid dendritic cells to kill tumors Holcmann, Martin Drobits, Barbara Sibilia, Maria Oncoimmunology Author's View We have provided evidence for a multifaceted antitumor-function of the Toll-like receptor 7 (TLR7) agonist imiquimod, which rapidly recruits plasmacytoid dendritic cells and possibly other immune cells into tumors by inducing the secretion of CCL2 by dermal cells. Imiquimod induces pDC maturation and their conversion into cytolytic killer cells, which are capable of eliminating tumors independently from the adaptive immune system. Landes Bioscience 2012-12-01 /pmc/articles/PMC3525638/ /pubmed/23264929 http://dx.doi.org/10.4161/onci.22033 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Holcmann, Martin
Drobits, Barbara
Sibilia, Maria
How imiquimod licenses plasmacytoid dendritic cells to kill tumors
title How imiquimod licenses plasmacytoid dendritic cells to kill tumors
title_full How imiquimod licenses plasmacytoid dendritic cells to kill tumors
title_fullStr How imiquimod licenses plasmacytoid dendritic cells to kill tumors
title_full_unstemmed How imiquimod licenses plasmacytoid dendritic cells to kill tumors
title_short How imiquimod licenses plasmacytoid dendritic cells to kill tumors
title_sort how imiquimod licenses plasmacytoid dendritic cells to kill tumors
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525638/
https://www.ncbi.nlm.nih.gov/pubmed/23264929
http://dx.doi.org/10.4161/onci.22033
work_keys_str_mv AT holcmannmartin howimiquimodlicensesplasmacytoiddendriticcellstokilltumors
AT drobitsbarbara howimiquimodlicensesplasmacytoiddendriticcellstokilltumors
AT sibiliamaria howimiquimodlicensesplasmacytoiddendriticcellstokilltumors

Ejemplares similares